Palantir's revenue rocketed past analyst forecasts as the AI-powered firm ramped up commercial and government deals, while facing renewed political scrutiny in the UK over its government contracts.
Financial Performance Exceeds Expectations
The US tech firm posted revenue of $1.6bn (£1.2bn) in the first three months of the year, above investor expectations of $1.5bn and 85 per cent ahead of the same period last year. The company raised its full-year revenue guidance to $7.6bn, driven by confidence in an accelerating US market, according to co-founder and chief executive Alex Karp. He noted that this growth was achieved despite having a smaller headcount compared to two years ago.
Matt Britzman, senior equity analyst at Hargreaves Lansdown, commented: "The key point is that this growth is not just about companies testing AI in small pockets – Palantir is increasingly being used in real-world operations, where the stakes are high, and customers need AI to deliver clear, measurable results." He added: "Management struck a very confident tone, pointing to strong US demand, expanding customer commitments and a sharp uplift in full-year guidance. That all supports the idea that Palantir has become one of the clearest ways to play the shift from AI hype to implementation."
Political Controversy in the UK
Palantir's results come as the company finds itself dragged into the UK political arena amid renewed scrutiny over its relationships with government departments, including its £330m NHS data platform contract. Last month, the company's UK chief executive, Louis Mosley, was forced to respond to a series of claims made by Green party leader Zack Polanski, including erroneous assertions about the company's management and operations.
Responding to concerns about Palantir's role in NHS England, Mosley stated that the firm has no more access to NHS data "than Microsoft has to the contents of your Word documents", adding: "We don't have access to patient medical records." He also highlighted operational outcomes linked to the company's software, including 110,000 additional operations and a seven per cent increase in patients finding out whether they have cancer within 28 days.
Palantir also holds contracts with the Ministry of Defence (MoD) and is used by several UK police forces, while the Metropolitan Police is exploring wider use of AI tools in investigations.
Market Reaction
Palantir's shares have risen by around 20 per cent over the past year, though the stock dipped slightly in after-hours trading following the publication of its latest earnings. Britzman cautioned: "Palantir looks to be one of the best pure plays on applied AI, but investors need to recognise that expectations are already very high."
